Nasopharyngeal Cancer - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 79 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Nasopharyngeal Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Nasopharyngeal Cancer - Pipeline Review, H2 2014', provides an overview of the Nasopharyngeal Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nasopharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Nasopharyngeal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Nasopharyngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Nasopharyngeal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Nasopharyngeal Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Nasopharyngeal Cancer - Overview 9
Pipeline Products for Nasopharyngeal Cancer - Comparative Analysis 10
Nasopharyngeal Cancer - Therapeutics under Development by Companies 11
Nasopharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes 13
Nasopharyngeal Cancer - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Nasopharyngeal Cancer - Products under Development by Companies 18
Nasopharyngeal Cancer - Products under Investigation by Universities/Institutes 19
Nasopharyngeal Cancer - Companies Involved in Therapeutics Development 20
F. Hoffmann-La Roche Ltd. 20
Gilead Sciences, Inc. 21
Astex Pharmaceuticals, Inc. 22
Cyclacel Pharmaceuticals, Inc. 23
BioDiem Ltd 24
Pharmacyclics, Inc. 25
Ambrx, Inc. 26
Otsuka Holdings Co., Ltd. 27
National Cancer Centre Singapore 28
Nasopharyngeal Cancer - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
nimotuzumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
seliciclib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Autologous Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes + [carboplatin]+ [gemcitabine] - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Vaccine for Epstein-Barr Viral Infections and Nasopharyngeal Cancer - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Cell Therapy for Metastatic Nasopharyngeal Carcinoma - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Dendritic Cells + Cytokine Induced Killer Cells - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Stem Cell Therapy for Oncology - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
abexinostat hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Cell Therapy for Oncology and Infectious Disease - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
OPB-51602 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Cell Therapy 3 for Oncology - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Cell Therapy for Nasopharingeal Carcinoma - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Recombinant Adenoviral Human p53 Gene Therapy - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
AT-13387 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecules for Nasopharyngeal and Colon Cancers - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Cell Therapy for Oncology - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
EBV-nRNA - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
RO-5203280 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Vaccine to Target EBV for Nasopharyngeal Carcinoma - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Nasopharyngeal Cancer - Recent Pipeline Updates 68
Nasopharyngeal Cancer - Dormant Projects 72
Nasopharyngeal Cancer - Product Development Milestones 73
Featured News & Press Releases 73
Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer 73
May 29, 2009: Cyclacel Reports Initial Phase 2 Seliciclib Data In Patients With Nasopharyngeal Carcinoma At 2009 Asco Annual Meeting 74
Apr 21, 2009: Cyclacel & Dartmouth Researchers Reports Novel Mechanism Of Action For Seliciclib At AACR 74
Mar 05, 2009: Cyclacel Announces Phase 1 Data Elucidating Pharmacodynamics & Mechanism Of Action Of Seliciclib In Nasopharyngeal Cancer 75
Oct 07, 2008: Epstein-Barr Virus Protein Contributes to Cancer 76
Aug 28, 2008: CYCLACEL Announces Recommendations Of Data Review Committee For Seliciclib Phase 2b Non-Small Cell Lung Cancer APPRAISE Trial 76
Jun 28, 2007: Cyclacel Pharmaceuticals Announces Results Of Phase II Seliciclib Combination Studies 77
Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 79
Disclaimer 79

List of Tables
Number of Products under Development for Nasopharyngeal Cancer, H2 2014 9
Number of Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 20
Nasopharyngeal Cancer - Pipeline by Gilead Sciences, Inc., H2 2014 21
Nasopharyngeal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 22
Nasopharyngeal Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2014 23
Nasopharyngeal Cancer - Pipeline by BioDiem Ltd, H2 2014 24
Nasopharyngeal Cancer - Pipeline by Pharmacyclics, Inc., H2 2014 25
Nasopharyngeal Cancer - Pipeline by Ambrx, Inc., H2 2014 26
Nasopharyngeal Cancer - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 27
Nasopharyngeal Cancer - Pipeline by National Cancer Centre Singapore, H2 2014 28
Assessment by Monotherapy Products, H2 2014 29
Assessment by Combination Products, H2 2014 30
Number of Products by Stage and Target, H2 2014 33
Number of Products by Stage and Mechanism of Action, H2 2014 36
Number of Products by Stage and Route of Administration, H2 2014 38
Number of Products by Stage and Molecule Type, H2 2014 40
Nasopharyngeal Cancer Therapeutics - Recent Pipeline Updates, H2 2014 68
Nasopharyngeal Cancer - Dormant Projects, H2 2014 72